RetinalGeniX applies for dry AMD, Alzheimer’s treatment patents
Click Here to Manage Email Alerts
RetinalGeniX Technologies announced that it submitted patent applications for investigational drug candidates RTG-2023 and RTG-2024, for age-related macular degeneration and Alzheimer’s, respectively.
“The company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs,” Jerry Katzman, MD, RetinalGeniX CEO, said in a company press release. “It’s a new approach to exploring potential therapies for these chronic systemic diseases.”
RTG-2023 was developed to treat dry age-related macular degeneration (AMD). According to the release, the only FDA-approved treatments intended to prevent dry AMD from progressing to the wet form and to treat the wet form are intraocular injections.
RTG-2024 was developed to treat Alzheimer’s disease, a condition that 6.7 million Americans aged 65 years and older live with, according to the Alzheimer’s Association. Currently available treatments focus on improving symptoms, but they do not address underlying brain changes or alter the course of the disease, RetinalGeniX said.
Katzman and Fred Chasalow, PhD, serve as co-developers of the investigational new drug applications for RTG-2023 and RTG-2024.
Collapse
Press Release
Click Here to Manage Email Alerts